Bristol-Myers Squibb Co (LTS:0R1F)
$ 54.48 -1.095 (-1.97%) Market Cap: 109.81 Bil Enterprise Value: 153.11 Bil PE Ratio: 0 PB Ratio: 6.41 GF Score: 84/100

Bristol-Myers Squibb Co Three-Part Investor Series: Early Pipeline and Immuno-Oncology Transcript

Jun 22, 2020 / 03:30PM GMT
Release Date Price: $56.4 (+1.02%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Bristol Myers Squibb Early Pipeline & Immuno-Oncology Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker, Tim Power. Sir, please go ahead.

Timothy Power
Bristol-Myers Squibb Company - VP & Head of IR

Thanks, Latif, and good morning, everyone. Thanks for joining us today for the first of our 3-part investor series. The plan for today is that we'll have a presentation followed by a Q&A session. And so if you're not participating via the webcast, you can always go ahead and download the materials from bms.com.

Joining me today for the presentation are Giovanni Caforio, Chairman and Chief Executive Officer; Rupert Vessey, Executive Vice President, Research and Early Development; Samit Hirawat, Chief Medical Officer, Global Drug Development; and Chris Boerner, Chief Commercialization Officer. And also with me today for the Q&A session are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot